- Home
- MURA vs SCNX Comparison
MURA vs SCNX Comparison
Compare MURA & SCNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MURA
- SCNX
- Stock Information
- Founded
- MURA 2013
- SCNX 2010
- Country
- MURA Ireland
- SCNX United States
- Employees
- MURA N/A
- SCNX N/A
- Industry
- MURA
- SCNX Other Pharmaceuticals
- Sector
- MURA
- SCNX Health Care
- Exchange
- MURA Nasdaq
- SCNX Nasdaq
- Market Cap
- MURA 57.2M
- SCNX 65.4M
- IPO Year
- MURA N/A
- SCNX 2020
- Fundamental
- Price
- MURA $4.00
- SCNX $4.63
- Analyst Decision
- MURA Strong Buy
- SCNX
- Analyst Count
- MURA 4
- SCNX 0
- Target Price
- MURA $16.00
- SCNX N/A
- AVG Volume (30 Days)
- MURA 239.2K
- SCNX 10.5K
- Earning Date
- MURA 11-13-2024
- SCNX 02-10-2025
- Dividend Yield
- MURA N/A
- SCNX N/A
- EPS Growth
- MURA N/A
- SCNX N/A
- EPS
- MURA N/A
- SCNX 3.55
- Revenue
- MURA N/A
- SCNX N/A
- Revenue This Year
- MURA N/A
- SCNX $1,085.75
- Revenue Next Year
- MURA N/A
- SCNX N/A
- P/E Ratio
- MURA N/A
- SCNX $2.01
- Revenue Growth
- MURA N/A
- SCNX 166.67
- 52 Week Low
- MURA $2.87
- SCNX $3.69
- 52 Week High
- MURA $5.62
- SCNX $44.56
- Technical
- Relative Strength Index (RSI)
- MURA 66.06
- SCNX N/A
- Support Level
- MURA $3.55
- SCNX N/A
- Resistance Level
- MURA $4.05
- SCNX N/A
- Average True Range (ATR)
- MURA 0.24
- SCNX 0.00
- MACD
- MURA 0.07
- SCNX 0.00
- Stochastic Oscillator
- MURA 91.35
- SCNX 0.00
About MURA Mural Oncology plc
Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.
About SCNX Scienture Holdings Inc. Common Stock
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on providing value to patients and caregivers by offering novel specialty products to satisfy unmet market needs and optimize the prescription journey and patient engagement in the U.S.